Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis

NCT03205345 is registered in ClinicalTrials.gov with Conatus Pharmaceuticals Inc. as lead sponsor.

NCT NCT03205345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03205345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Lead sponsor
Conatus Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
June 28, 2017
Completion date
August 31, 2019
Enrollment
210 (estimated)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

decompensated cirrhosis